Journey Medical Corporation Expands Emrosi™ Access with Third Major GPO Contract: Key Milestone for Commercial Growth
Scottsdale, AZ – April 21, 2026 – Journey Medical Corporation (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in prescription dermatology products, has announced a significant expansion in payer access for its newly launched product, Emrosi™ (minocycline hydrochloride modified-release capsules) for the treatment of rosacea in adults.
Key Highlights
- Secures Contract with Third Major Group Purchasing Organization (GPO): Journey Medical has completed a third major GPO contract for Emrosi™, marking a crucial milestone in its commercial launch strategy.
- Payer Access Expanded: As of April 1, 2026, Emrosi™ now has coverage for over 150 million commercial lives, up from approximately 100 million, representing about 85% of all commercial lives in the United States.
- Growth in Prescription Demand Expected: The expanded access is expected to drive further growth in prescription demand and facilitate Journey Medical’s ambition to make Emrosi™ the standard of care in rosacea treatment.
- Strategic Focus: The company will now emphasize health plan formulary adoption at both the national and regional levels, aiming to increase coverage and profitability while reducing reliance on co-pay bridging programs.
Potential Shareholder Impact and Price Sensitivity
- Significant Market Penetration: With 85% access to the U.S. commercial market for Emrosi™, Journey Medical is well-positioned for rapid uptake, which could materially boost revenues and market share in the dermatology segment.
- Improved Profitability Outlook: As formulary adoption rises and the need for co-pay support decreases, margin improvements are anticipated, potentially enhancing shareholder value.
- Milestone Achievement: Securing all three major GPO contracts is a critical catalyst that may positively influence investor sentiment and the company’s share price, given the implications for sustained commercial growth and competitive positioning.
Management Commentary
Claude Maraoui, Co-Founder, President, and CEO, commented: “Our focus on delivering cost-effective access to high-quality dermatology therapies is expected to expand coverage and improve patient access, positioning Emrosi™ for sustained commercial growth. Now that our contracts have been secured with the three major GPOs, we look forward to continuing to increase coverage for Emrosi™ for patients nationwide by converting access into coverage. As formulary adoption continues to increase, we expect there to be less reliance on our co-pay bridging program and an improvement in profitability for the brand.”
About Emrosi™ and Rosacea Market Opportunity
- Product Profile: Emrosi™ is a 40 mg minocycline hydrochloride modified-release capsule (10 mg immediate release, 30 mg extended release) indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults.
- Rosacea Prevalence: Rosacea is a chronic skin disorder affecting over 17 million Americans and up to 415 million people worldwide, predominantly impacting adults aged 30-50. The condition has a substantial psychosocial burden, with many patients reporting reduced self-esteem and work productivity.
Important Safety Information
- Adverse Events: The most common adverse reaction (≥1%) is dyspepsia. Other serious risks include hypersensitivity, anaphylaxis, Stevens-Johnson syndrome, DRESS syndrome, liver injury, and possible effects on teeth and bone growth in children and pregnant women.
- Precautions: Patients should avoid sunlight, and regular monitoring of organ systems is advised during treatment. Use only as indicated to manage antibiotic resistance risks.
Corporate Overview
- Journey Medical Corporation markets eight branded FDA-approved dermatology drugs and leverages a specialized sales and marketing model.
- The company operates from Scottsdale, Arizona, and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO).
- Journey Medical’s common stock is registered with the SEC, and it files periodic reports.
Forward-Looking Considerations
- Investors should note the company’s forward-looking statements regarding growth, profitability, and risk factors, including regulatory, competitive, and operational uncertainties that could materially impact future results.
- Key risks include competition from generics, dependence on third parties, market acceptance, cybersecurity threats, and the need for additional capital.
Investor and Media Contacts
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Investors should review the company’s filings with the SEC and consult their professional advisors before making investment decisions.
View Journey Medical Corp Historical chart here
